<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Urol</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Urol</journal-id><journal-title-group><journal-title>European Urology</journal-title></journal-title-group><issn pub-type="ppub">0302-2838</issn><issn pub-type="epub">1873-7560</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29307509</article-id><article-id pub-id-type="pmc">5954168</article-id><article-id pub-id-type="publisher-id">S0302-2838(17)31063-1</article-id><article-id pub-id-type="doi">10.1016/j.eururo.2017.12.017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kass-Iliyya</surname><given-names>Antoine</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Jovic</surname><given-names>Gordana</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>Claire</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Fisher</surname><given-names>Cyril</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Syndikus</surname><given-names>Isabel</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Jose</surname><given-names>Chakiath</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Scrase</surname><given-names>Christopher D.</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>John D.</given-names></name><xref rid="aff0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Nicol</surname><given-names>David</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Sydes</surname><given-names>Matthew R.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Dearnaley</surname><given-names>David</given-names></name><email>David.Dearnaley@icr.ac.uk</email><xref rid="aff0040" ref-type="aff">h</xref><xref rid="cor0005" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>MRC Clinical Trials Unit at UCL, London, UK</aff><aff id="aff0010"><label>b</label>North Bristol Trust, Bristol, UK</aff><aff id="aff0015"><label>c</label>Royal Marsden Hospital, London, UK</aff><aff id="aff0020"><label>d</label>Clatterbridge Centre for Oncology, Wirral, UK</aff><aff id="aff0025"><label>e</label>Department of Radiation Oncology, Auckland City Hospital, Auckland, New Zealand</aff><aff id="aff0030"><label>f</label>Ipswich Hospital, Ipswich, UK</aff><aff id="aff0035"><label>g</label>Taunton &amp; Somerset National Health Service Foundation Trust, Musgrove Park Hospital, Taunton, UK</aff><aff id="aff0040"><label>h</label>Institute of Cancer Research and Royal Marsden Hospitals, Sutton and London, UK</aff><author-notes><corresp id="cor0005"><label>⁎</label>Corresponding author. Institute of Cancer Research/Royal Marsden Hospitals, Academic Unit of Radiotherapy, Downs Road, Sutton SM2 5PT, UK. Tel. +44 208 661 3271. <email>David.Dearnaley@icr.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2018</year></pub-date><volume>73</volume><issue>6</issue><fpage>968</fpage><lpage>976</lpage><history><date date-type="accepted"><day>14</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Elsevier B.V. on behalf of European Association of Urology. All rights reserved.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>European Association of Urology</copyright-holder><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title><offsets xml_i="4799" xml_f="4809" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4820" xml_f="4901" txt_i="22" txt_f="103">The importance of 2-yr postradiotherapy prostate biopsy status remains uncertain.</offsets></p></sec><sec><title><offsets xml_i="4923" xml_f="4932" txt_i="105" txt_f="114">Objective</offsets></title><p><offsets xml_i="4943" xml_f="5051" txt_i="115" txt_f="223">To assess the value of 2 year post treatment biopsies in a randomised trial of radiotherapy dose escalation.</offsets></p></sec><sec><title><offsets xml_i="5073" xml_f="5106" txt_i="225" txt_f="258">Design, setting, and participants</offsets></title><p><offsets xml_i="5117" xml_f="5441" txt_i="259" txt_f="583">Between 1998 and 2001, 843 men with localised prostate cancer were randomised to receive either control-64 Gy or escalated-74 Gy conformal radiotherapy (CFRT) in the MRC RT01 trial in combination with 3–6-mo neoadjuvant androgen deprivation therapy. Prostate biopsies were planned at 2 yr from start of CFRT in suitable men.</offsets></p></sec><sec><title><offsets xml_i="5463" xml_f="5508" txt_i="585" txt_f="630">Outcome measurements and statistical analysis</offsets></title><p><offsets xml_i="5519" xml_f="5786" txt_i="631" txt_f="898">Prostate biopsy results and prostate-specific antigen (PSA) levels performed at 2 yr post-CFRT were evaluated with long-term biochemical progression free survival (bPFS) and overall survival. Outcome measures were timed from the 2-yr biopsy using a landmark approach.</offsets></p></sec><sec><title><offsets xml_i="5808" xml_f="5831" txt_i="900" txt_f="923">Results and limitations</offsets></title><p><offsets xml_i="5842" xml_f="6365" txt_i="924" txt_f="1447">A 2-yr biopsy was performed in 312/843 patients. One hundred and seventy-seven patients were included in the per-protocol group with median follow-up of 7.8 yr from biopsy. Median PSA at biopsy was 0.5 ng/ml. Sixty-four bPFS events were reported: 46/145 (32%) in patients with negative, 6/18 (33%) suspicious, and 12/14 (86%) positive biopsies. A positive biopsy was prognostic of worse bPFS, going forward, compared with negative and suspicious biopsies, hazard ratio (HR) = 4.81 (95% confidence interval [CI]: 2.50–9.26, </offsets><italic><offsets xml_i="6373" xml_f="6374" txt_i="1447" txt_f="1448">p</offsets></italic><offsets xml_i="6383" xml_f="6457" txt_i="1448" txt_f="1519"> &lt; 0.001). The estimate for survival was HR = 1.58 (95% CI: 0.52–4.78, </offsets><italic><offsets xml_i="6465" xml_f="6466" txt_i="1519" txt_f="1520">p</offsets></italic><offsets xml_i="6475" xml_f="6762" txt_i="1520" txt_f="1807"> = 0.42). PSA values at 2 yr between 1.01 ng/ml and 2.09 ng/ml were also associated with subsequent PSA failures (HR = 2.71, 95% CI: 1.98–3.71), bPFS events (HR = 2.45, 95% CI: 1.81–3.32), and prostate cancer-specific survival (HR = 2.87, 95% CI: 1.08–7.64) compared with PSA ≤1.0 ng/ml.</offsets></p></sec><sec><title><offsets xml_i="6784" xml_f="6795" txt_i="1809" txt_f="1820">Conclusions</offsets></title><p><offsets xml_i="6806" xml_f="7081" txt_i="1821" txt_f="2096">Two-year postradiotherapy prostate biopsies have limited value in patients with PSA control but both positive biopsy and higher PSA status are strongly associated with future bPFS events. A policy of selected biopsy may provide an opportunity for early salvage interventions.</offsets></p></sec><sec><title><offsets xml_i="7103" xml_f="7118" txt_i="2098" txt_f="2113">Patient summary</offsets></title><p><offsets xml_i="7129" xml_f="7340" txt_i="2114" txt_f="2325">Routine 2-yr postradiotherapy biopsy is not recommended but can be considered in selected patients with unfavourable post-treatment prostate-specific antigen levels who are suitable for early salvage treatments.</offsets></p></sec></abstract><abstract abstract-type="teaser" id="abs0005"><title><offsets xml_i="7414" xml_f="7431" txt_i="2338" txt_f="2355">Take Home Message</offsets></title><p><offsets xml_i="7442" xml_f="7715" txt_i="2356" txt_f="2629">Two-year postradiotherapy biopsy results from a randomised controlled trial indicate that routine biopsy is not indicated but biopsy should be used selectively to guide local salvage treatments in patients with unfavourable post-treatment prostate-specific antigen results.</offsets></p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Prostate cancer</kwd><kwd>Biopsy</kwd><kwd>Conformal radiotherapy</kwd></kwd-group></article-meta><notes><p id="misc0005"><bold>Associate Editor:</bold> James Catto</p></notes></front><body><sec id="sec0005"><label><offsets xml_i="7997" xml_f="7998" txt_i="2637" txt_f="2638">1</offsets></label><title><offsets xml_i="8013" xml_f="8025" txt_i="2638" txt_f="2650">Introduction</offsets></title><p id="par0005"><offsets xml_i="8049" xml_f="8210" txt_i="2651" txt_f="2812">There is controversy over the value of prostate biopsy after radiotherapy (RT) treatment for prostate cancer in predicting future survival and recurrence trends </offsets><xref rid="bib0150" ref-type="bibr"><offsets xml_i="8246" xml_f="8249" txt_i="2812" txt_f="2815">[1]</offsets></xref><offsets xml_i="8256" xml_f="8258" txt_i="2815" txt_f="2817">, </offsets><xref rid="bib0155" ref-type="bibr"><offsets xml_i="8294" xml_f="8297" txt_i="2817" txt_f="2820">[2]</offsets></xref><offsets xml_i="8304" xml_f="8380" txt_i="2820" txt_f="2896">. The inherent difficulties in interpreting postradiation prostate biopsies </offsets><xref rid="bib0160" ref-type="bibr"><offsets xml_i="8416" xml_f="8419" txt_i="2896" txt_f="2899">[3]</offsets></xref><offsets xml_i="8426" xml_f="8530" txt_i="2899" txt_f="3003"> and debate regarding the optimal time of performing those biopsies have contributed to the uncertainty </offsets><xref rid="bib0150" ref-type="bibr"><offsets xml_i="8566" xml_f="8569" txt_i="3003" txt_f="3006">[1]</offsets></xref><offsets xml_i="8576" xml_f="8578" txt_i="3006" txt_f="3008">, </offsets><xref rid="bib0165" ref-type="bibr"><offsets xml_i="8614" xml_f="8617" txt_i="3008" txt_f="3011">[4]</offsets></xref><offsets xml_i="8624" xml_f="8625" txt_i="3011" txt_f="3012">.</offsets></p><p id="par0010"><offsets xml_i="8645" xml_f="8919" txt_i="3013" txt_f="3287">Previous reports have suggested that men with a positive biopsy post-RT have a much worse prognosis than those with negative biopsies. However, most of these reports included a small number of patients, short-term follow-up, and heterogeneous methods of pathology reporting </offsets><xref rid="bib0170" ref-type="bibr"><offsets xml_i="8955" xml_f="8958" txt_i="3287" txt_f="3290">[5]</offsets></xref><offsets xml_i="8965" xml_f="8967" txt_i="3290" txt_f="3292">, </offsets><xref rid="bib0175" ref-type="bibr"><offsets xml_i="9003" xml_f="9006" txt_i="3292" txt_f="3295">[6]</offsets></xref><offsets xml_i="9013" xml_f="9015" txt_i="3295" txt_f="3297">, </offsets><xref rid="bib0180" ref-type="bibr"><offsets xml_i="9051" xml_f="9054" txt_i="3297" txt_f="3300">[7]</offsets></xref><offsets xml_i="9061" xml_f="9063" txt_i="3300" txt_f="3302">, </offsets><xref rid="bib0185" ref-type="bibr"><offsets xml_i="9099" xml_f="9102" txt_i="3302" txt_f="3305">[8]</offsets></xref><offsets xml_i="9109" xml_f="9286" txt_i="3305" txt_f="3482">. Our study included a large, prospectively-recruited cohort of patients participating in a randomised controlled trial, with 10-yr follow-up and a single reference pathologist.</offsets></p></sec><sec id="sec0010"><label><offsets xml_i="9321" xml_f="9322" txt_i="3484" txt_f="3485">2</offsets></label><title><offsets xml_i="9337" xml_f="9358" txt_i="3485" txt_f="3506">Materials and methods</offsets></title><sec id="sec0015"><label><offsets xml_i="9391" xml_f="9394" txt_i="3507" txt_f="3510">2.1</offsets></label><title><offsets xml_i="9409" xml_f="9448" txt_i="3510" txt_f="3549">Design of the RT01 trial and treatments</offsets></title><p id="par0015"><offsets xml_i="9472" xml_f="9592" txt_i="3550" txt_f="3670">The design, objectives, patient eligibility criteria, treatment methods of the RT01 trial have been detailed previously </offsets><xref rid="bib0190" ref-type="bibr"><offsets xml_i="9628" xml_f="9631" txt_i="3670" txt_f="3673">[9]</offsets></xref><offsets xml_i="9638" xml_f="9640" txt_i="3673" txt_f="3675">, </offsets><xref rid="bib0195" ref-type="bibr"><offsets xml_i="9676" xml_f="9680" txt_i="3675" txt_f="3679">[10]</offsets></xref><offsets xml_i="9687" xml_f="9689" txt_i="3679" txt_f="3681">, </offsets><xref rid="bib0200" ref-type="bibr"><offsets xml_i="9725" xml_f="9729" txt_i="3681" txt_f="3685">[11]</offsets></xref><offsets xml_i="9736" xml_f="9895" txt_i="3685" txt_f="3841">. In brief, consenting men with histologically confirmed T1b–T3a N0 M0 prostate cancer and prostate-specific antigen (PSA) levels &lt;50 ng/ml were registered.</offsets></p><p id="par0020"><offsets xml_i="9915" xml_f="10380" txt_i="3842" txt_f="4307">Patients having conformally-delivered radiotherapy were randomised to receive either a control schedule of 64 Gy/32f RT (Std-64 Gy) or an escalated schedule of 74 Gy/37f (Esc-74 Gy). Neo-adjuvant androgen deprivation therapy was administered 3–6 mo prior to RT and was maintained until the end of RT. Based on pathology grading, PSA, and T-stage, men were stratified into two groups according to the risk of seminal vesicles involvement (low or moderate/high risk) </offsets><xref rid="bib0205" ref-type="bibr"><offsets xml_i="10416" xml_f="10420" txt_i="4307" txt_f="4311">[12]</offsets></xref><offsets xml_i="10427" xml_f="10428" txt_i="4311" txt_f="4312">.</offsets></p><p id="par0025"><offsets xml_i="10448" xml_f="10644" txt_i="4313" txt_f="4509">The trial followed the principles of the Declaration of Helsinki. Each centre attained ethical approval and participants gave separate informed consent for trial participation and the 2-yr biopsy.</offsets></p></sec><sec id="sec0020"><label><offsets xml_i="10679" xml_f="10682" txt_i="4511" txt_f="4514">2.2</offsets></label><title><offsets xml_i="10697" xml_f="10714" txt_i="4514" txt_f="4531">Trial assessments</offsets></title><sec id="sec0025"><label><offsets xml_i="10747" xml_f="10752" txt_i="4532" txt_f="4537">2.2.1</offsets></label><title><offsets xml_i="10767" xml_f="10778" txt_i="4537" txt_f="4548">Assessments</offsets></title><p id="par0030"><offsets xml_i="10802" xml_f="11601" txt_i="4549" txt_f="5348">Before treatment each patient underwent a prostate biopsy, PSA measurement and local (digital rectal examination, transrectal ultrasound/magnetic resonance imaging [MRI]), lymph node (computed tomography [CT]/MRI), and metastases staging (bone scan, chest x-ray). PSA and digital rectal examination were performed post-RT (10 wk, 18 wk) and were repeated at 6 mo, 12 mo, 18 mo, and 24 mo, and annually thereafter. Full assessment of the disease was undertaken if there was clinical or biochemical evidence of disease recurrence, which included CT or MRI of the pelvis and bone scan. Prostate biopsy was performed 2 yr from start of RT in consenting patients without evidence of biochemical or clinical progression. This entailed transrectal two to four core biopsies or more if clinically indicated.</offsets></p></sec><sec id="sec0030"><label><offsets xml_i="11636" xml_f="11641" txt_i="5350" txt_f="5355">2.2.2</offsets></label><title><offsets xml_i="11656" xml_f="11678" txt_i="5355" txt_f="5377">Two-year biopsy review</offsets></title><p id="par0035"><offsets xml_i="11702" xml_f="12257" txt_i="5378" txt_f="5933">The window for the 2-yr biopsy was determined retrospectively as 18–36 mo after starting RT. These biopsies were reviewed by local and central pathologists. The biopsy outcomes at central review were classified as: (1) positive, if haematoxylin and eosin staining showed evidence of residual malignancy, regardless of the scarcity of malignant cells, (b) negative, if no malignant cells were present, or (c) suspicious, if it was not possible to distinguish cancerous cells from radiation atypia, even after immunostaining (CK-34beta-E12) or PSA staining.</offsets></p></sec><sec id="sec0035"><label><offsets xml_i="12292" xml_f="12297" txt_i="5935" txt_f="5940">2.2.3</offsets></label><title><offsets xml_i="12312" xml_f="12375" txt_i="5940" txt_f="6003">Definition of biochemical failure and assessment of progression</offsets></title><p id="par0040"><offsets xml_i="12399" xml_f="12530" txt_i="6004" txt_f="6135">Biochemical failure was considered to have occurred if both of two conditions were met in close accord with the Phoenix definition </offsets><xref rid="bib0195" ref-type="bibr"><offsets xml_i="12566" xml_f="12570" txt_i="6135" txt_f="6139">[10]</offsets></xref><offsets xml_i="12577" xml_f="12868" txt_i="6139" txt_f="6427">: (1) PSA &gt;2 ng/ml measured ≥6 mo after RT commenced and (2) rise in PSA from nadir level by ≥50%. Full re-evaluation of disease (CT/MRI/bone scan) was triggered if there was clinical or biochemical evidence of recurrence (trigger values: PSA ≥ 10 ng/ml and ≥50% of presenting PSA level) </offsets><xref rid="bib0210" ref-type="bibr"><offsets xml_i="12904" xml_f="12908" txt_i="6427" txt_f="6431">[13]</offsets></xref><offsets xml_i="12915" xml_f="12916" txt_i="6431" txt_f="6432">.</offsets></p></sec></sec><sec id="sec0040"><label><offsets xml_i="12957" xml_f="12960" txt_i="6435" txt_f="6438">2.3</offsets></label><title><offsets xml_i="12975" xml_f="12991" txt_i="6438" txt_f="6454">Outcome measures</offsets></title><p id="par0045"><offsets xml_i="13015" xml_f="13364" txt_i="6455" txt_f="6804">The coprimary outcome measures in RT01 were survival and biochemical progression-free survival (bPFS). Survival was defined as time to death from any cause or censoring at date of last contact, bPFS as time to the first of: biochemical failure, death from prostate cancer, or development of local, nodal, metastatic disease, or date of last contact.</offsets></p></sec><sec id="sec0045"><label><offsets xml_i="13399" xml_f="13402" txt_i="6806" txt_f="6809">2.4</offsets></label><title><offsets xml_i="13417" xml_f="13437" txt_i="6809" txt_f="6829">Analysis populations</offsets></title><sec id="sec0050"><label><offsets xml_i="13470" xml_f="13475" txt_i="6830" txt_f="6835">2.4.1</offsets></label><title><offsets xml_i="13490" xml_f="13508" txt_i="6835" txt_f="6853">Per-protocol group</offsets></title><p id="par0050"><offsets xml_i="13532" xml_f="13881" txt_i="6854" txt_f="7203">This is the main focus of this analysis. The per-protocol group (PPG) included only patients without a prior bPFS event who had 2-yr biopsy within the window and which was reviewed centrally. Exclusion criteria were: (1) bPFS event before or at biopsy and (2) biopsies performed outside the 18–36 mo window. Analyses were timed from the 2-yr biopsy.</offsets></p></sec><sec id="sec0055"><label><offsets xml_i="13916" xml_f="13921" txt_i="7205" txt_f="7210">2.4.2</offsets></label><title><offsets xml_i="13936" xml_f="13981" txt_i="7210" txt_f="7255">Local histopathology review 2-yr biopsy group</offsets></title><p id="par0055"><offsets xml_i="14005" xml_f="14229" txt_i="7256" txt_f="7480">This included patients without a prior bPFS event who had 2-yr biopsy which was reviewed locally (with or without central review). The same exclusion criteria applied as for the PPG. Analyses were timed from the 2-yr biopsy.</offsets></p></sec><sec id="sec0060"><label><offsets xml_i="14264" xml_f="14269" txt_i="7482" txt_f="7487">2.4.3</offsets></label><title><offsets xml_i="14284" xml_f="14301" txt_i="7487" txt_f="7504">Exploratory group</offsets></title><p id="par0060"><offsets xml_i="14325" xml_f="14440" txt_i="7505" txt_f="7620">This included only patients with a bPFS event at or before the 2-yr biopsy. Analyses were timed from randomisation.</offsets></p></sec><sec id="sec0065"><label><offsets xml_i="14475" xml_f="14480" txt_i="7622" txt_f="7627">2.4.4</offsets></label><title><offsets xml_i="14495" xml_f="14513" txt_i="7627" txt_f="7645">Two-year PSA group</offsets></title><p id="par0065"><offsets xml_i="14537" xml_f="14827" txt_i="7646" txt_f="7933">This included all patients with a PSA value within 20–28 mo after randomisation (whether biopsied or unbiopsied), who were bPFS-event-free up to the point of the 2-yr PSA test, and with PSA &lt;2 ng/ml at the time of the test. All outcome measures were timed from the date of 2-yr PSA test.</offsets></p></sec></sec><sec id="sec0070"><label><offsets xml_i="14868" xml_f="14871" txt_i="7936" txt_f="7939">2.5</offsets></label><title><offsets xml_i="14886" xml_f="14912" txt_i="7939" txt_f="7965">Statistical considerations</offsets></title><p id="par0070"><offsets xml_i="14936" xml_f="15178" txt_i="7966" txt_f="8208">Kaplan-Meier plots and log-rank test were used to study the impact of the biopsy outcome on bPFS and survival. Cox models adjusted for seminal vesicle involvement risk group and allocated treatment were used to estimate the hazard ratio (HR).</offsets></p><p id="par0075"><offsets xml_i="15198" xml_f="15405" txt_i="8209" txt_f="8416">Multivariate Cox proportional hazards models were applied to bPFS and overall survival, using backward selection. Covariates were kept in the final model if they were statistically significant at a level of </offsets><italic><offsets xml_i="15413" xml_f="15414" txt_i="8416" txt_f="8417">p</offsets></italic><offsets xml_i="15423" xml_f="15682" txt_i="8417" txt_f="8673"> &lt; 0.10. Multiple logistic regression was used to study the impact of covariates on the outcome of the biopsy. Negative and suspicious outcomes were grouped together since there was no evidence of a difference for each outcome measures using log-rank test.</offsets></p><p id="par0080"><offsets xml_i="15702" xml_f="15968" txt_i="8674" txt_f="8940">Kappa statistic was used to determine agreement between the local and central review. Fisher's exact test was applied to test the association between the seminal vesicle (SV) involvement and outcome of the biopsy. All analyses used a two-sided 5% significance level.</offsets></p></sec></sec><sec id="sec0075"><label><offsets xml_i="16009" xml_f="16010" txt_i="8943" txt_f="8944">3</offsets></label><title><offsets xml_i="16025" xml_f="16032" txt_i="8944" txt_f="8951">Results</offsets></title><p id="par0085"><offsets xml_i="16056" xml_f="16128" txt_i="8952" txt_f="9024">Data were frozen on August 2, 2011, matching the previous results paper </offsets><xref rid="bib0195" ref-type="bibr"><offsets xml_i="16164" xml_f="16168" txt_i="9024" txt_f="9028">[10]</offsets></xref><offsets xml_i="16175" xml_f="16176" txt_i="9028" txt_f="9029">.</offsets></p><sec id="sec0080"><label><offsets xml_i="16205" xml_f="16208" txt_i="9030" txt_f="9033">3.1</offsets></label><title><offsets xml_i="16223" xml_f="16242" txt_i="9033" txt_f="9052">Patient populations</offsets></title><p id="par0090"><offsets xml_i="16266" xml_f="16555" txt_i="9053" txt_f="9342">Of the 843 men randomised in RT01, 312 men (37%) underwent a 2-yr biopsy of the prostate. Median time from starting RT to biopsy was 2.1 yr (interquartile range: 2.0–2.2). Three hundred and eleven out of 312 (99.7%) biopsies were reviewed locally and 223/312 (71%) were reviewed centrally.</offsets></p><p id="par0095"><offsets xml_i="16575" xml_f="16724" txt_i="9343" txt_f="9492">Seventy out of 312 (22%) patients were excluded from the PPG, mainly (65/70) because a bPFS event was reported before or on the date of 2-yr biopsy (</offsets><xref rid="fig0005" ref-type="fig"><offsets xml_i="16759" xml_f="16765" txt_i="9492" txt_f="9498">Fig. 1</offsets></xref><offsets xml_i="16772" xml_f="16774" txt_i="9498" txt_f="9500">).</offsets><fig id="fig0005"><label><offsets xml_i="16799" xml_f="16805" txt_i="9500" txt_f="9506">Fig. 1</offsets></label><caption><p><offsets xml_i="16825" xml_f="16841" txt_i="9506" txt_f="9522">CONSORT diagram.</offsets></p><p><offsets xml_i="16848" xml_f="17036" txt_i="9523" txt_f="9711">bPFS = biochemical progression-free survival; LB = local histopathology review 2-yr biopsy; MFS = metastasis-free survival; OS = overall survival; PCa = prostate cancer; RT = radiotherapy.</offsets></p><p><sup><offsets xml_i="17048" xml_f="17049" txt_i="9712" txt_f="9713">a</offsets></sup><offsets xml_i="17055" xml_f="17090" txt_i="9713" txt_f="9748"> 1 patient satisfies both criteria.</offsets></p><p><sup><offsets xml_i="17102" xml_f="17103" txt_i="9749" txt_f="9750">b</offsets></sup><offsets xml_i="17109" xml_f="17144" txt_i="9750" txt_f="9785"> 1 patient satisfies both criteria.</offsets></p></caption><graphic xlink:href="gr1"></graphic></fig></p><p id="par0100"><offsets xml_i="17220" xml_f="17641" txt_i="9787" txt_f="10208">In the remaining 242 patients (local histopathology review 2-yr biopsy group [LBG]), biopsy outcomes were: negative 198/242 (82%), suspicious 19/242 (8%), and positive 25/242 (10%). The PPG consists of 177 patients whose biopsy outcomes were negative 145/177 (82%), suspicious 18/177 (10%), and positive 14/177 (8%). Kappa statistic showed good agreement between local and central pathologists assessments (kappa = 0.71; </offsets><xref rid="tbl0005" ref-type="table"><offsets xml_i="17678" xml_f="17685" txt_i="10208" txt_f="10215">Table 1</offsets></xref><offsets xml_i="17692" xml_f="17694" txt_i="10215" txt_f="10217">) </offsets><xref rid="bib0215" ref-type="bibr"><offsets xml_i="17730" xml_f="17734" txt_i="10217" txt_f="10221">[14]</offsets></xref><offsets xml_i="17741" xml_f="17742" txt_i="10221" txt_f="10222">.</offsets><table-wrap id="tbl0005" position="float"><label><offsets xml_i="17791" xml_f="17798" txt_i="10222" txt_f="10229">Table 1</offsets></label><caption><p><offsets xml_i="17818" xml_f="17884" txt_i="10229" txt_f="10295">Agreement between local and reference histopathologist assessments</offsets></p></caption><alt-text id="at1"><offsets xml_i="17917" xml_f="17924" txt_i="10296" txt_f="10303">Table 1</offsets></alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="5" align="center"><offsets xml_i="18023" xml_f="18049" txt_i="10303" txt_f="10329">Reference histopathologist</offsets><hr></hr></th></tr><tr><th align="left"><offsets xml_i="18089" xml_f="18111" txt_i="10329" txt_f="10351">Local histopathologist</offsets></th><th align="center"><offsets xml_i="18135" xml_f="18143" txt_i="10351" txt_f="10359">Negative</offsets></th><th align="center"><offsets xml_i="18167" xml_f="18177" txt_i="10359" txt_f="10369">Suspicious</offsets></th><th align="center"><offsets xml_i="18201" xml_f="18209" txt_i="10369" txt_f="10377">Positive</offsets></th><th align="center"><offsets xml_i="18233" xml_f="18241" txt_i="10377" txt_f="10385">Not done</offsets></th><th align="center"><offsets xml_i="18265" xml_f="18270" txt_i="10385" txt_f="10390">Total</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="18316" xml_f="18324" txt_i="10390" txt_f="10398">Negative</offsets></td><td align="char"><offsets xml_i="18346" xml_f="18349" txt_i="10399" txt_f="10402">153</offsets></td><td align="char"><offsets xml_i="18371" xml_f="18372" txt_i="10403" txt_f="10404">6</offsets></td><td align="char"><offsets xml_i="18394" xml_f="18395" txt_i="10405" txt_f="10406">0</offsets></td><td align="char"><offsets xml_i="18417" xml_f="18419" txt_i="10407" txt_f="10409">65</offsets></td><td align="char"><offsets xml_i="18441" xml_f="18444" txt_i="10410" txt_f="10413">224</offsets></td></tr><tr><td align="left"><offsets xml_i="18475" xml_f="18485" txt_i="10414" txt_f="10424">Suspicious</offsets></td><td align="char"><offsets xml_i="18507" xml_f="18508" txt_i="10425" txt_f="10426">7</offsets></td><td align="char"><offsets xml_i="18530" xml_f="18532" txt_i="10427" txt_f="10429">13</offsets></td><td align="char"><offsets xml_i="18554" xml_f="18555" txt_i="10430" txt_f="10431">4</offsets></td><td align="char"><offsets xml_i="18577" xml_f="18578" txt_i="10432" txt_f="10433">5</offsets></td><td align="char"><offsets xml_i="18600" xml_f="18602" txt_i="10434" txt_f="10436">29</offsets></td></tr><tr><td align="left"><offsets xml_i="18633" xml_f="18641" txt_i="10437" txt_f="10445">Positive</offsets></td><td align="char"><offsets xml_i="18663" xml_f="18664" txt_i="10446" txt_f="10447">3</offsets></td><td align="char"><offsets xml_i="18686" xml_f="18687" txt_i="10448" txt_f="10449">8</offsets></td><td align="char"><offsets xml_i="18709" xml_f="18711" txt_i="10450" txt_f="10452">29</offsets></td><td align="char"><offsets xml_i="18733" xml_f="18735" txt_i="10453" txt_f="10455">18</offsets></td><td align="char"><offsets xml_i="18757" xml_f="18759" txt_i="10456" txt_f="10458">58</offsets></td></tr><tr><td align="left"><offsets xml_i="18790" xml_f="18798" txt_i="10459" txt_f="10467">Not done</offsets></td><td align="char"><offsets xml_i="18820" xml_f="18821" txt_i="10468" txt_f="10469">0</offsets></td><td align="char"><offsets xml_i="18843" xml_f="18844" txt_i="10470" txt_f="10471">0</offsets></td><td align="char"><offsets xml_i="18866" xml_f="18867" txt_i="10472" txt_f="10473">0</offsets></td><td align="char"><offsets xml_i="18889" xml_f="18890" txt_i="10474" txt_f="10475">1</offsets></td><td align="char"><offsets xml_i="18912" xml_f="18913" txt_i="10476" txt_f="10477">1</offsets></td></tr><tr><td align="left"><offsets xml_i="18944" xml_f="18949" txt_i="10478" txt_f="10483">Total</offsets></td><td align="char"><offsets xml_i="18971" xml_f="18974" txt_i="10484" txt_f="10487">163</offsets></td><td align="char"><offsets xml_i="18996" xml_f="18998" txt_i="10488" txt_f="10490">27</offsets></td><td align="char"><offsets xml_i="19020" xml_f="19022" txt_i="10491" txt_f="10493">33</offsets></td><td align="char"><offsets xml_i="19044" xml_f="19046" txt_i="10494" txt_f="10496">89</offsets></td><td align="char"><offsets xml_i="19068" xml_f="19071" txt_i="10497" txt_f="10500">312</offsets><xref rid="tblfn0005" ref-type="table-fn"><offsets xml_i="19113" xml_f="19114" txt_i="10500" txt_f="10501">a</offsets></xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn0005"><label><offsets xml_i="19190" xml_f="19191" txt_i="10502" txt_f="10503">a</offsets></label><p id="npar0005"><offsets xml_i="19216" xml_f="19257" txt_i="10503" txt_f="10544">Biopsy was performed in 312/843 patients.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0085"><label><offsets xml_i="19332" xml_f="19335" txt_i="10547" txt_f="10550">3.2</offsets></label><title><offsets xml_i="19350" xml_f="19372" txt_i="10550" txt_f="10572">PPG analyses (N = 177)</offsets></title><sec id="sec0090"><label><offsets xml_i="19405" xml_f="19410" txt_i="10573" txt_f="10578">3.2.1</offsets></label><title><offsets xml_i="19425" xml_f="19449" txt_i="10578" txt_f="10602">Baseline characteristics</offsets></title><p id="par0105"><offsets xml_i="19473" xml_f="19600" txt_i="10603" txt_f="10730">The median age, Gleason score and SV involvement risk groups of 177 patients in PPG were similar to the main trial population (</offsets><xref rid="tbl0010" ref-type="table"><offsets xml_i="19637" xml_f="19644" txt_i="10730" txt_f="10737">Table 2</offsets></xref><offsets xml_i="19651" xml_f="19653" txt_i="10737" txt_f="10739">).</offsets><table-wrap id="tbl0010" position="float"><label><offsets xml_i="19702" xml_f="19709" txt_i="10739" txt_f="10746">Table 2</offsets></label><caption><p><offsets xml_i="19729" xml_f="19827" txt_i="10746" txt_f="10844">Baseline patient and tumour characteristics, by inclusion into per-protocol group (central review)</offsets></p></caption><alt-text id="at2"><offsets xml_i="19860" xml_f="19867" txt_i="10845" txt_f="10852">Table 2</offsets></alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="3" align="center"><offsets xml_i="19966" xml_f="19984" txt_i="10852" txt_f="10870">Per-protocol group</offsets><hr></hr></th><th align="center"><offsets xml_i="20017" xml_f="20035" txt_i="10870" txt_f="10888">All other patients</offsets><xref rid="tblfn0010" ref-type="table-fn"><offsets xml_i="20077" xml_f="20078" txt_i="10888" txt_f="10889">a</offsets></xref></th></tr><tr><th></th><th align="center"><offsets xml_i="20127" xml_f="20135" txt_i="10889" txt_f="10897">Negative</offsets></th><th align="center"><offsets xml_i="20159" xml_f="20169" txt_i="10897" txt_f="10907">Suspicious</offsets></th><th align="center"><offsets xml_i="20193" xml_f="20201" txt_i="10907" txt_f="10915">Positive</offsets></th><th></th></tr><tr><th></th><th align="center"><italic><offsets xml_i="20260" xml_f="20261" txt_i="10915" txt_f="10916">N</offsets></italic><offsets xml_i="20270" xml_f="20274" txt_i="10916" txt_f="10920"> (%)</offsets></th><th align="center"><italic><offsets xml_i="20306" xml_f="20307" txt_i="10920" txt_f="10921">N</offsets></italic><offsets xml_i="20316" xml_f="20320" txt_i="10921" txt_f="10925"> (%)</offsets></th><th align="center"><italic><offsets xml_i="20352" xml_f="20353" txt_i="10925" txt_f="10926">N</offsets></italic><offsets xml_i="20362" xml_f="20366" txt_i="10926" txt_f="10930"> (%)</offsets></th><th></th></tr></thead><tbody><tr><td colspan="5" align="left"><offsets xml_i="20433" xml_f="20441" txt_i="10930" txt_f="10938">Age (yr)</offsets></td></tr><tr><td align="left"><offsets xml_i="20472" xml_f="20485" txt_i="10939" txt_f="10952"> Median (IQR)</offsets></td><td align="left"><offsets xml_i="20507" xml_f="20517" txt_i="10953" txt_f="10963">69 (65–72)</offsets></td><td align="left"><offsets xml_i="20539" xml_f="20549" txt_i="10964" txt_f="10974">70 (66–72)</offsets></td><td align="left"><offsets xml_i="20571" xml_f="20581" txt_i="10975" txt_f="10985">67 (63–71)</offsets></td><td align="left"><offsets xml_i="20603" xml_f="20613" txt_i="10986" txt_f="10996">67 (63–71)</offsets></td></tr><tr><td align="left"><offsets xml_i="20644" xml_f="20649" txt_i="10997" txt_f="11002"> Mean</offsets></td><td align="left"><offsets xml_i="20671" xml_f="20673" txt_i="11003" txt_f="11005">68</offsets></td><td align="left"><offsets xml_i="20695" xml_f="20697" txt_i="11006" txt_f="11008">68</offsets></td><td align="left"><offsets xml_i="20719" xml_f="20721" txt_i="11009" txt_f="11011">66</offsets></td><td align="left"><offsets xml_i="20743" xml_f="20745" txt_i="11012" txt_f="11014">67</offsets></td></tr><tr><td align="left"><offsets xml_i="20776" xml_f="20782" txt_i="11015" txt_f="11021"> Range</offsets></td><td align="left"><offsets xml_i="20804" xml_f="20809" txt_i="11022" txt_f="11027">47–80</offsets></td><td align="left"><offsets xml_i="20831" xml_f="20836" txt_i="11028" txt_f="11033">58–76</offsets></td><td align="left"><offsets xml_i="20858" xml_f="20863" txt_i="11034" txt_f="11039">51–74</offsets></td><td align="left"><offsets xml_i="20885" xml_f="20890" txt_i="11040" txt_f="11045">47–81</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="20933" xml_f="20940" txt_i="11046" txt_f="11053">T stage</offsets></td></tr><tr><td align="left"><offsets xml_i="20971" xml_f="20979" txt_i="11054" txt_f="11062"> T1b–T2a</offsets></td><td align="left"><offsets xml_i="21001" xml_f="21009" txt_i="11063" txt_f="11071">107 (74)</offsets></td><td align="left"><offsets xml_i="21031" xml_f="21038" txt_i="11072" txt_f="11079">10 (56)</offsets></td><td align="left"><offsets xml_i="21060" xml_f="21066" txt_i="11080" txt_f="11086">8 (57)</offsets></td><td align="left"><offsets xml_i="21088" xml_f="21096" txt_i="11087" txt_f="11095">375 (57)</offsets></td></tr><tr><td align="left"><offsets xml_i="21127" xml_f="21131" txt_i="11096" txt_f="11100"> T2b</offsets></td><td align="left"><offsets xml_i="21153" xml_f="21160" txt_i="11101" txt_f="11108">19 (13)</offsets></td><td align="left"><offsets xml_i="21182" xml_f="21188" txt_i="11109" txt_f="11115">4 (56)</offsets></td><td align="left"><offsets xml_i="21210" xml_f="21216" txt_i="11116" txt_f="11122">3 (21)</offsets></td><td align="left"><offsets xml_i="21238" xml_f="21246" txt_i="11123" txt_f="11131">158 (24)</offsets></td></tr><tr><td align="left"><offsets xml_i="21277" xml_f="21280" txt_i="11132" txt_f="11135"> T3</offsets></td><td align="left"><offsets xml_i="21302" xml_f="21309" txt_i="11136" txt_f="11143">19 (13)</offsets></td><td align="left"><offsets xml_i="21331" xml_f="21337" txt_i="11144" txt_f="11150">4 (22)</offsets></td><td align="left"><offsets xml_i="21359" xml_f="21365" txt_i="11151" txt_f="11157">3 (21)</offsets></td><td align="left"><offsets xml_i="21387" xml_f="21395" txt_i="11158" txt_f="11166">121 (19)</offsets></td></tr><tr><td align="left"><offsets xml_i="21426" xml_f="21436" txt_i="11167" txt_f="11177"> Not known</offsets></td><td align="left"><offsets xml_i="21458" xml_f="21464" txt_i="11178" txt_f="11184">0 (NA)</offsets></td><td align="left"><offsets xml_i="21486" xml_f="21492" txt_i="11185" txt_f="11191">0 (NA)</offsets></td><td align="left"><offsets xml_i="21514" xml_f="21520" txt_i="11192" txt_f="11198">0 (NA)</offsets></td><td align="left"><offsets xml_i="21542" xml_f="21549" txt_i="11199" txt_f="11206">12 (NA)</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="21592" xml_f="21613" txt_i="11207" txt_f="11228">Imputed Gleason score</offsets></td></tr><tr><td align="left"><offsets xml_i="21644" xml_f="21647" txt_i="11229" txt_f="11232"> ≤6</offsets></td><td align="left"><offsets xml_i="21669" xml_f="21676" txt_i="11233" txt_f="11240">96 (66)</offsets></td><td align="left"><offsets xml_i="21698" xml_f="21705" txt_i="11241" txt_f="11248">11 (91)</offsets></td><td align="left"><offsets xml_i="21727" xml_f="21733" txt_i="11249" txt_f="11255">9 (64)</offsets></td><td align="left"><offsets xml_i="21755" xml_f="21763" txt_i="11256" txt_f="11264">394 (60)</offsets></td></tr><tr><td align="left"><offsets xml_i="21794" xml_f="21796" txt_i="11265" txt_f="11267"> 7</offsets></td><td align="left"><offsets xml_i="21818" xml_f="21826" txt_i="11268" txt_f="11276">31 (21%0</offsets></td><td align="left"><offsets xml_i="21848" xml_f="21854" txt_i="11277" txt_f="11283">7 (39)</offsets></td><td align="left"><offsets xml_i="21876" xml_f="21882" txt_i="11284" txt_f="11290">4 (29)</offsets></td><td align="left"><offsets xml_i="21904" xml_f="21912" txt_i="11291" txt_f="11299">180 (27)</offsets></td></tr><tr><td align="left"><offsets xml_i="21943" xml_f="21946" txt_i="11300" txt_f="11303"> ≥8</offsets></td><td align="left"><offsets xml_i="21968" xml_f="21975" txt_i="11304" txt_f="11311">18 (12)</offsets></td><td align="left"><offsets xml_i="21997" xml_f="22002" txt_i="11312" txt_f="11317">0 (0)</offsets></td><td align="left"><offsets xml_i="22024" xml_f="22029" txt_i="11318" txt_f="11323">1 (7)</offsets></td><td align="left"><offsets xml_i="22051" xml_f="22058" txt_i="11324" txt_f="11331">87 (13)</offsets></td></tr><tr><td align="left"><offsets xml_i="22089" xml_f="22099" txt_i="11332" txt_f="11342"> Not known</offsets></td><td align="left"><offsets xml_i="22121" xml_f="22127" txt_i="11343" txt_f="11349">0 (NA)</offsets></td><td align="left"><offsets xml_i="22149" xml_f="22155" txt_i="11350" txt_f="11356">0 (NA)</offsets></td><td align="left"><offsets xml_i="22177" xml_f="22183" txt_i="11357" txt_f="11363">0 (NA)</offsets></td><td align="left"><offsets xml_i="22205" xml_f="22211" txt_i="11364" txt_f="11370">5 (NA)</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="22254" xml_f="22265" txt_i="11371" txt_f="11382">PSA (ng/ml)</offsets></td></tr><tr><td align="left"><offsets xml_i="22296" xml_f="22309" txt_i="11383" txt_f="11396"> Median (IQR)</offsets></td><td align="left"><offsets xml_i="22331" xml_f="22346" txt_i="11397" txt_f="11412">10.0 (6.7–15.4)</offsets></td><td align="left"><offsets xml_i="22368" xml_f="22383" txt_i="11413" txt_f="11428">11.6 (8.1–13.9)</offsets></td><td align="left"><offsets xml_i="22405" xml_f="22421" txt_i="11429" txt_f="11445">15.0 (10.7–19.1)</offsets></td><td align="left"><offsets xml_i="22443" xml_f="22458" txt_i="11446" txt_f="11461">13.4 (8.4–21.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="22489" xml_f="22499" txt_i="11462" txt_f="11472"> Mean (SD)</offsets></td><td align="left"><offsets xml_i="22521" xml_f="22531" txt_i="11473" txt_f="11483">12.7 (8.5)</offsets></td><td align="left"><offsets xml_i="22553" xml_f="22564" txt_i="11484" txt_f="11495">13.5 (10.2)</offsets></td><td align="left"><offsets xml_i="22586" xml_f="22596" txt_i="11496" txt_f="11506">15.0 (6.1)</offsets></td><td align="left"><offsets xml_i="22618" xml_f="22629" txt_i="11507" txt_f="11518">16.0 (10.0)</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="22672" xml_f="22698" txt_i="11519" txt_f="11545">Seminal vesicle risk group</offsets><xref rid="tblfn0015" ref-type="table-fn"><offsets xml_i="22740" xml_f="22741" txt_i="11545" txt_f="11546">b</offsets></xref></td></tr><tr><td align="left"><offsets xml_i="22779" xml_f="22783" txt_i="11547" txt_f="11551"> Low</offsets></td><td align="left"><offsets xml_i="22805" xml_f="22812" txt_i="11552" txt_f="11559">62 (43)</offsets></td><td align="left"><offsets xml_i="22834" xml_f="22841" txt_i="11560" txt_f="11567">10 (56)</offsets></td><td align="left"><offsets xml_i="22863" xml_f="22869" txt_i="11568" txt_f="11574">3 (21)</offsets></td><td align="left"><offsets xml_i="22891" xml_f="22899" txt_i="11575" txt_f="11583">200 (30)</offsets></td></tr><tr><td align="left"><offsets xml_i="22930" xml_f="22944" txt_i="11584" txt_f="11598"> Moderate/high</offsets></td><td align="left"><offsets xml_i="22966" xml_f="22973" txt_i="11599" txt_f="11606">83 (57)</offsets></td><td align="left"><offsets xml_i="22995" xml_f="23001" txt_i="11607" txt_f="11613">8 (44)</offsets></td><td align="left"><offsets xml_i="23023" xml_f="23030" txt_i="11614" txt_f="11621">11 (79)</offsets></td><td align="left"><offsets xml_i="23052" xml_f="23060" txt_i="11622" txt_f="11630">466 (70)</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="23103" xml_f="23122" txt_i="11631" txt_f="11650">Allocated treatment</offsets></td></tr><tr><td align="left"><offsets xml_i="23153" xml_f="23162" txt_i="11651" txt_f="11660"> Std-64Gy</offsets></td><td align="left"><offsets xml_i="23184" xml_f="23191" txt_i="11661" txt_f="11668">70 (48)</offsets></td><td align="left"><offsets xml_i="23213" xml_f="23220" txt_i="11669" txt_f="11676">12 (67)</offsets></td><td align="left"><offsets xml_i="23242" xml_f="23249" txt_i="11677" txt_f="11684">11 (79)</offsets></td><td align="left"><offsets xml_i="23271" xml_f="23279" txt_i="11685" txt_f="11693">328 (49)</offsets></td></tr><tr><td align="left"><offsets xml_i="23310" xml_f="23319" txt_i="11694" txt_f="11703"> Esc-74Gy</offsets></td><td align="left"><offsets xml_i="23341" xml_f="23348" txt_i="11704" txt_f="11711">75 (52)</offsets></td><td align="left"><offsets xml_i="23370" xml_f="23376" txt_i="11712" txt_f="11718">6 (33)</offsets></td><td align="left"><offsets xml_i="23398" xml_f="23404" txt_i="11719" txt_f="11725">3 (21)</offsets></td><td align="left"><offsets xml_i="23426" xml_f="23434" txt_i="11726" txt_f="11734">338 (51)</offsets></td></tr><tr><td align="left"><offsets xml_i="23465" xml_f="23471" txt_i="11735" txt_f="11741"> Total</offsets></td><td align="left"><offsets xml_i="23493" xml_f="23496" txt_i="11742" txt_f="11745">145</offsets></td><td align="left"><offsets xml_i="23518" xml_f="23520" txt_i="11746" txt_f="11748">18</offsets></td><td align="left"><offsets xml_i="23542" xml_f="23544" txt_i="11749" txt_f="11751">14</offsets></td><td align="left"><offsets xml_i="23566" xml_f="23569" txt_i="11752" txt_f="11755">666</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="23619" xml_f="23781" txt_i="11756" txt_f="11918">Esc-74 Gy = escalated 74 Gy; IQR = interquartile range; NA = not applicable; PSA = prostate-specific antigen; SD = standard deviation; Std-64 Gy = standard 64 Gy.</offsets></p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0010"><label><offsets xml_i="23851" xml_f="23852" txt_i="11919" txt_f="11920">a</offsets></label><p id="npar0010"><offsets xml_i="23877" xml_f="23899" txt_i="11920" txt_f="11942">Biopsy not performed (</offsets><italic><offsets xml_i="23907" xml_f="23908" txt_i="11942" txt_f="11943">N</offsets></italic><offsets xml_i="23917" xml_f="23996" txt_i="11943" txt_f="12022"> = 531, patient did not meet the criteria for inclusion in per-protocol group (</offsets><italic><offsets xml_i="24004" xml_f="24005" txt_i="12022" txt_f="12023">N</offsets></italic><offsets xml_i="24014" xml_f="24021" txt_i="12023" txt_f="12030"> = 70; </offsets><xref rid="fig0005" ref-type="fig"><offsets xml_i="24056" xml_f="24062" txt_i="12030" txt_f="12036">Fig. 1</offsets></xref><offsets xml_i="24069" xml_f="24118" txt_i="12036" txt_f="12085">), biopsy not reviewed by reference pathologist (</offsets><italic><offsets xml_i="24126" xml_f="24127" txt_i="12085" txt_f="12086">N</offsets></italic><offsets xml_i="24136" xml_f="24143" txt_i="12086" txt_f="12093"> = 65).</offsets></p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0015"><label><offsets xml_i="24213" xml_f="24214" txt_i="12094" txt_f="12095">b</offsets></label><p id="npar0015"><offsets xml_i="24239" xml_f="24254" txt_i="12095" txt_f="12110">See Diaz et al </offsets><xref rid="bib0205" ref-type="bibr"><offsets xml_i="24290" xml_f="24294" txt_i="12110" txt_f="12114">[12]</offsets></xref><offsets xml_i="24301" xml_f="24302" txt_i="12114" txt_f="12115">.</offsets></p></fn></table-wrap-foot></table-wrap></p><p id="par0110"><offsets xml_i="24362" xml_f="24585" txt_i="12117" txt_f="12340">A similar proportion of the Std-64 Gy group were included in the PPG biopsy cohort (93/421; 22%) as the Esc-74 Gy group (84/422; 20%) but biopsy-positive rates were lower in Esc–74 Gy (3/84; 4%) than Std-64 Gy (11/93; 12%).</offsets></p><p id="par0115"><offsets xml_i="24605" xml_f="24927" txt_i="12341" txt_f="12663">In a multivariate analysis (logistic regression), considering age, T-stage, Gleason score, pretreatment PSA, SV involvement risk group and allocated treatment, the strongest associations with biopsy outcome were PSA value, as a continuous measure, at 2 yr (odds ratio [OR] = 1.90, 95% confidence interval [CI]: 0.97–3.71, </offsets><italic><offsets xml_i="24935" xml_f="24936" txt_i="12663" txt_f="12664">p</offsets></italic><offsets xml_i="24945" xml_f="25006" txt_i="12664" txt_f="12725"> = 0.06), allocated treatment (OR = 0.31, 95% CI: 0.08–1.24, </offsets><italic><offsets xml_i="25014" xml_f="25015" txt_i="12725" txt_f="12726">p</offsets></italic><offsets xml_i="25024" xml_f="25096" txt_i="12726" txt_f="12798"> = 0.10), and SV involvement risk group (OR = 2.61, 95% CI: 0.44–15.31, </offsets><italic><offsets xml_i="25104" xml_f="25105" txt_i="12798" txt_f="12799">p</offsets></italic><offsets xml_i="25114" xml_f="25198" txt_i="12799" txt_f="12883"> = 0.29) but none of these reached statistical significance (Supplementary Table 1).</offsets></p></sec><sec id="sec0095"><label><offsets xml_i="25233" xml_f="25238" txt_i="12885" txt_f="12890">3.2.2</offsets></label><title><offsets xml_i="25253" xml_f="25257" txt_i="12890" txt_f="12894">bPFS</offsets></title><p id="par0120"><offsets xml_i="25281" xml_f="25558" txt_i="12895" txt_f="13172">Sixty-four bPFS events were reported in the PPG: 46/145 (32%) in patients with negative, 6/18 (33%) suspicious and 12/14 (86%) positive biopsies, respectively. Patients with a positive biopsy were more likely to report a bPFS event in the future (HR = 4.81, 95% CI: 2.50–9.26, </offsets><italic><offsets xml_i="25566" xml_f="25567" txt_i="13172" txt_f="13173">p</offsets></italic><offsets xml_i="25576" xml_f="25589" txt_i="13173" txt_f="13183"> &lt; 0.001; </offsets><xref rid="fig0010" ref-type="fig"><offsets xml_i="25624" xml_f="25630" txt_i="13183" txt_f="13189">Fig. 2</offsets></xref><offsets xml_i="25637" xml_f="25640" txt_i="13189" txt_f="13192">A, </offsets><xref rid="tbl0015" ref-type="table"><offsets xml_i="25677" xml_f="25684" txt_i="13192" txt_f="13199">Table 3</offsets></xref><offsets xml_i="25691" xml_f="25693" txt_i="13199" txt_f="13201">).</offsets><fig id="fig0010"><label><offsets xml_i="25718" xml_f="25724" txt_i="13201" txt_f="13207">Fig. 2</offsets></label><caption><p><offsets xml_i="25744" xml_f="26140" txt_i="13207" txt_f="13603">Outcome measures, per-protocol (PP) group (central review). (A) Biochemical progression-free survival (bPFS), by biopsy outcome. (B) bPFS, negative and suspicious versus positive biopsy. (C) Metastases-free survival (MFS), by biopsy outcome. (D) MFS, negative and suspicious versus positive biopsy. (E) Overall survival (OS), by biopsy outcome. (F) OS, negative and suspicious vs positive biopsy.</offsets></p></caption><graphic xlink:href="gr2"></graphic></fig><table-wrap id="tbl0015" position="float"><label><offsets xml_i="26245" xml_f="26252" txt_i="13604" txt_f="13611">Table 3</offsets></label><caption><p><offsets xml_i="26272" xml_f="26325" txt_i="13611" txt_f="13664">Outcome measures, per-protocol group (central review)</offsets></p></caption><alt-text id="at3"><offsets xml_i="26358" xml_f="26365" txt_i="13665" txt_f="13672">Table 3</offsets></alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th></th><th align="center"><offsets xml_i="26470" xml_f="26499" txt_i="13672" txt_f="13701">Negative or suspicious biopsy</offsets></th><th align="center"><offsets xml_i="26523" xml_f="26538" txt_i="13701" txt_f="13716">Positive biopsy</offsets></th></tr><tr><th align="left"><offsets xml_i="26569" xml_f="26584" txt_i="13716" txt_f="13731">Outcome measure</offsets><xref rid="tblfn0020" ref-type="table-fn"><offsets xml_i="26626" xml_f="26627" txt_i="13731" txt_f="13732">a</offsets></xref></th><th align="center"><offsets xml_i="26658" xml_f="26660" txt_i="13732" txt_f="13734">HR</offsets><xref rid="tblfn0025" ref-type="table-fn"><offsets xml_i="26702" xml_f="26703" txt_i="13734" txt_f="13735">b</offsets></xref><offsets xml_i="26710" xml_f="26719" txt_i="13735" txt_f="13744"> (95% CI)</offsets></th><th align="center"><italic><offsets xml_i="26751" xml_f="26752" txt_i="13744" txt_f="13745">p</offsets></italic><offsets xml_i="26761" xml_f="26767" txt_i="13745" txt_f="13751"> value</offsets></th><th align="center"><offsets xml_i="26791" xml_f="26806" txt_i="13751" txt_f="13766">Events/patients</offsets></th><th align="center"><offsets xml_i="26830" xml_f="26845" txt_i="13766" txt_f="13781">Events/patients</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="26891" xml_f="26928" txt_i="13781" txt_f="13818">Biochemical progression-free survival</offsets></td><td align="char"><offsets xml_i="26950" xml_f="26966" txt_i="13819" txt_f="13835">4.81 (2.50–9.26)</offsets></td><td align="char"><offsets xml_i="26988" xml_f="26997" txt_i="13836" txt_f="13842">&lt;0.001</offsets></td><td align="char"><offsets xml_i="27019" xml_f="27025" txt_i="13843" txt_f="13849">52/163</offsets></td><td align="char"><offsets xml_i="27047" xml_f="27052" txt_i="13850" txt_f="13855">12/14</offsets></td></tr><tr><td align="left"><offsets xml_i="27083" xml_f="27107" txt_i="13856" txt_f="13880">Metastases-free survival</offsets></td><td align="char"><offsets xml_i="27129" xml_f="27145" txt_i="13881" txt_f="13897">1.97 (0.49–7.92)</offsets></td><td align="char"><offsets xml_i="27167" xml_f="27171" txt_i="13898" txt_f="13902">0.34</offsets></td><td align="char"><offsets xml_i="27193" xml_f="27198" txt_i="13903" txt_f="13908">9/163</offsets></td><td align="char"><offsets xml_i="27220" xml_f="27224" txt_i="13909" txt_f="13913">3/14</offsets></td></tr><tr><td align="left"><offsets xml_i="27255" xml_f="27271" txt_i="13914" txt_f="13930">Overall survival</offsets></td><td align="char"><offsets xml_i="27293" xml_f="27309" txt_i="13931" txt_f="13947">1.58 (0.52–4.78)</offsets></td><td align="char"><offsets xml_i="27331" xml_f="27335" txt_i="13948" txt_f="13952">0.42</offsets></td><td align="char"><offsets xml_i="27357" xml_f="27363" txt_i="13953" txt_f="13959">23/163</offsets></td><td align="char"><offsets xml_i="27385" xml_f="27389" txt_i="13960" txt_f="13964">4/14</offsets></td></tr><tr><td align="left"><offsets xml_i="27420" xml_f="27442" txt_i="13965" txt_f="13987">Prostate cancer deaths</offsets></td><td align="char"><offsets xml_i="27464" xml_f="27483" txt_i="13988" txt_f="14007">15.64 (1.41–173.66)</offsets></td><td align="char"><offsets xml_i="27505" xml_f="27509" txt_i="14008" txt_f="14012">0.02</offsets></td><td align="char"><offsets xml_i="27531" xml_f="27536" txt_i="14013" txt_f="14018">1/163</offsets></td><td align="char"><offsets xml_i="27558" xml_f="27562" txt_i="14019" txt_f="14023">3/14</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="27612" xml_f="27656" txt_i="14024" txt_f="14068">CI = confidence interval; HR = hazard ratio.</offsets></p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0020"><label><offsets xml_i="27726" xml_f="27727" txt_i="14069" txt_f="14070">a</offsets></label><p id="npar0020"><offsets xml_i="27752" xml_f="27775" txt_i="14070" txt_f="14093">Timed from 2-yr biopsy.</offsets></p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0025"><label><offsets xml_i="27845" xml_f="27846" txt_i="14094" txt_f="14095">b</offsets></label><p id="npar0025"><offsets xml_i="27871" xml_f="28019" txt_i="14095" txt_f="14243">HR comparing “positive” versus “negative or suspicious” biopsy outcome, adjusted for seminal vesicle involvement risk group and allocated treatment.</offsets></p></fn></table-wrap-foot></table-wrap></p><p id="par0125"><offsets xml_i="28079" xml_f="28215" txt_i="14245" txt_f="14381">The strongest associations with bPFS events on multivariate analysis were the outcome of the 2-yr biopsy (HR = 4.82, 95% CI: 2.53–9.19, </offsets><italic><offsets xml_i="28223" xml_f="28224" txt_i="14381" txt_f="14382">p</offsets></italic><offsets xml_i="28233" xml_f="28290" txt_i="14382" txt_f="14436"> &lt; 0.001), PSA at 2-yr (HR = 1.47, 95% CI: 1.20–1.81, </offsets><italic><offsets xml_i="28298" xml_f="28299" txt_i="14436" txt_f="14437">p</offsets></italic><offsets xml_i="28308" xml_f="28367" txt_i="14437" txt_f="14493"> &lt; 0.001), and ≥T3 stage (HR = 1.87, 95% CI: 1.03–3.40, </offsets><italic><offsets xml_i="28375" xml_f="28376" txt_i="14493" txt_f="14494">p</offsets></italic><offsets xml_i="28385" xml_f="28394" txt_i="14494" txt_f="14503"> = 0.04).</offsets></p><p id="par0130"><offsets xml_i="28414" xml_f="28610" txt_i="14504" txt_f="14700">Notably, 2/14 (14%) patients with positive prostate biopsies at 2-yr had no evidence of bPFS or clinical failure after completing 10-yr follow-up. Two-year PSA levels were 0.1 ng/ml and 0.2 ng/ml.</offsets></p></sec><sec id="sec0100"><label><offsets xml_i="28645" xml_f="28650" txt_i="14702" txt_f="14707">3.2.3</offsets></label><title><offsets xml_i="28665" xml_f="28719" txt_i="14707" txt_f="14761">Overall survival and prostate cancer-specific survival</offsets></title><p id="par0135"><offsets xml_i="28743" xml_f="28889" txt_i="14762" txt_f="14908">Twenty-seven deaths were reported: 21/145 (14%) in patients with negative, 2/18 (11%) suspicious, and 4/14 (29%) positive biopsies, respectively (</offsets><xref rid="fig0010" ref-type="fig"><offsets xml_i="28924" xml_f="28940" txt_i="14908" txt_f="14924">Figs. 2E and F2F</offsets></xref><offsets xml_i="28947" xml_f="29131" txt_i="14924" txt_f="15108">). There was no statistically significant increased risk of death from any cause in patients with positive compared with suspicious or negative biopsies: HR = 1.58 (95% CI: 0.52–4.78, </offsets><italic><offsets xml_i="29139" xml_f="29140" txt_i="15108" txt_f="15109">p</offsets></italic><offsets xml_i="29149" xml_f="29337" txt_i="15109" txt_f="15297"> = 0.42). Only 4/27 deaths were attributed to prostate cancer: 1/145 in patients with negative, 0/18 suspicious, and 3/14 positive biopsies, respectively: HR = 15.64 (95% CI: 1.41–173.66, </offsets><italic><offsets xml_i="29345" xml_f="29346" txt_i="15297" txt_f="15298">p</offsets></italic><offsets xml_i="29355" xml_f="29364" txt_i="15298" txt_f="15307"> = 0.02).</offsets></p></sec></sec><sec id="sec0105"><label><offsets xml_i="29405" xml_f="29408" txt_i="15310" txt_f="15313">3.3</offsets></label><title><offsets xml_i="29423" xml_f="29445" txt_i="15313" txt_f="15335">LBG analyses (N = 242)</offsets></title><sec id="sec0110"><label><offsets xml_i="29478" xml_f="29483" txt_i="15336" txt_f="15341">3.3.1</offsets></label><title><offsets xml_i="29498" xml_f="29522" txt_i="15341" txt_f="15365">Baseline characteristics</offsets></title><p id="par0140"><offsets xml_i="29546" xml_f="29698" txt_i="15366" txt_f="15518">The median age, Gleason score, and SV involvement risk groups of the 311 LBG patients were similar to the main trial population (Supplementary Table 2).</offsets></p></sec><sec id="sec0115"><label><offsets xml_i="29733" xml_f="29738" txt_i="15520" txt_f="15525">3.3.2</offsets></label><title><offsets xml_i="29753" xml_f="29782" txt_i="15525" txt_f="15554">All outcome measures: results</offsets></title><p id="par0145"><offsets xml_i="29806" xml_f="29909" txt_i="15555" txt_f="15658">Survival and bPFS results in the LBG group are broadly consistent with the PPG (Supplementary Table 3, </offsets><xref rid="fig0005" ref-type="fig"><offsets xml_i="29944" xml_f="29950" txt_i="15658" txt_f="15664">Fig. 1</offsets></xref><offsets xml_i="29957" xml_f="30013" txt_i="15664" txt_f="15720">), for example, for bPFS (HR = 1.64, 95% CI: 0.90–2.97, </offsets><italic><offsets xml_i="30021" xml_f="30022" txt_i="15720" txt_f="15721">p</offsets></italic><offsets xml_i="30031" xml_f="30266" txt_i="15721" txt_f="15953"> &lt; 0.001). Of the 37 deaths, only six (16%) were attributed to prostate cancer. Comparison of positive versus negative and suspicious biopsies in terms of prostate cancer-specific survival (PCSS) gave HR = 9.77 (95% CI: 1.61–59.20, </offsets><italic><offsets xml_i="30274" xml_f="30275" txt_i="15953" txt_f="15954">p</offsets></italic><offsets xml_i="30284" xml_f="30388" txt_i="15954" txt_f="16058"> = 0.01). The strongest associations with bPFS were PSA ≥1 ng/ml at 2-yr (HR = 1.54, 95% CI: 1.30–1.83, </offsets><italic><offsets xml_i="30396" xml_f="30397" txt_i="16058" txt_f="16059">p</offsets></italic><offsets xml_i="30406" xml_f="30464" txt_i="16059" txt_f="16114"> &lt; 0.001) and ≥T3 stage (HR = 1.97, 95% CI: 1.17–3.33, </offsets><italic><offsets xml_i="30472" xml_f="30473" txt_i="16114" txt_f="16115">p</offsets></italic><offsets xml_i="30482" xml_f="30491" txt_i="16115" txt_f="16124"> = 0.01).</offsets></p></sec></sec><sec id="sec0120"><label><offsets xml_i="30532" xml_f="30535" txt_i="16127" txt_f="16130">3.4</offsets></label><title><offsets xml_i="30550" xml_f="30592" txt_i="16130" txt_f="16172">Exploratory group (early failures, N = 65)</offsets></title><p id="par0150"></p></sec><sec id="sec0125"><label><offsets xml_i="30651" xml_f="30654" txt_i="16175" txt_f="16178">3.5</offsets></label><title><offsets xml_i="30669" xml_f="30765" txt_i="16178" txt_f="16274">Overall death and prostate cancer-specific mortality comparing biopsied and nonbiopsied patients</offsets></title><p id="par0155"><offsets xml_i="30789" xml_f="31534" txt_i="16275" txt_f="17020">The death rate was higher in the nonbiopsied patients; only 20.5% (64/312) of biopsied patients died compared with 32% (172/531) in the nonbiopsied group. Seventy patients were excluded from the LBG population, and 65/70 were excluded due to bPFS before 2 yr (the exploratory group [EG]). The death rate was much higher in this subgroup: 39% (27/70). Prostate cancer mortality was similar and low in the biopsied and unbiopsied populations who had PSA/clinical control at 2 yr with 6/242 (2%) and 19/448 (4%) deaths, respectively. However, it was considerably higher in patients who had PSA/clinical failure by 2 yr with 24% (17/70) and 59% (49/83) prostate cancer deaths in biopsied and unbiopsied cohorts, respectively (Supplementary Table 5).</offsets></p></sec><sec id="sec0130"><label><offsets xml_i="31569" xml_f="31572" txt_i="17022" txt_f="17025">3.6</offsets></label><title><offsets xml_i="31587" xml_f="31618" txt_i="17025" txt_f="17056">Prognostic value of PSA at 2 yr</offsets></title><p id="par0160"><offsets xml_i="31642" xml_f="31802" txt_i="17057" txt_f="17217">This can only be assessed in patients who had not previously reported a bPFS event and for whom a 2-yr PSA value was available: this was 621/843 (74%) patients.</offsets></p><sec id="sec0135"><label><offsets xml_i="31831" xml_f="31836" txt_i="17218" txt_f="17223">3.6.1</offsets></label><title><offsets xml_i="31851" xml_f="31895" txt_i="17223" txt_f="17267">Two-year PSA and centrally-reviewed biopsies</offsets></title><p id="par0165"><offsets xml_i="31919" xml_f="32164" txt_i="17268" txt_f="17513">Within these 621 patients, 2-yr biopsies had been performed in 251 (40%), with a central biopsy review in 179/251 (71%) patients. In these 179 patients, there was an association between higher 2-yr PSA values and positive biopsy (Fisher's test, </offsets><italic><offsets xml_i="32172" xml_f="32173" txt_i="17513" txt_f="17514">p</offsets></italic><offsets xml_i="32182" xml_f="32571" txt_i="17514" txt_f="17897"> &lt; 0.001); 11/31 (35%) patients with 2-yr PSA of 1.01–2 ng/ml had a positive biopsy on central review, compared with 10/148 (7%) with PSA &lt;1 ng/ml. The median 2-yr PSA value was 0.5 ng/ml and, splitting at this point, positive biopsies were seen on central review for 9/95 (9%) patients with 2-yr PSA ≤0.5 ng/ml, 0/48 with PSA 0.51–0.99 ng/ml (0%) and 12/36 (33%) with PSA 1–2 ng/ml.</offsets></p><p id="par0170"><offsets xml_i="32591" xml_f="32937" txt_i="17898" txt_f="18244">Multivariate analyses in the 621 patients showed that 2-yr PSA was associated with subsequent PSA failures (HR = 2.71, 95% CI: 1.98–3.71), bPFS events (HR = 2.45, 95% CI: 1.81–3.32), PCSS (HR: 2.87, 95% CI: 1.08–7.64), but not clearly on metastasis-free survival (HR = 1.76, 95% CI: 0.86–3.60) or overall survival (HR = 0.95, 95% CI: 0.60, 1.51; </offsets><xref rid="fig0015" ref-type="fig"><offsets xml_i="32972" xml_f="32978" txt_i="18244" txt_f="18250">Fig. 3</offsets></xref><offsets xml_i="32985" xml_f="33010" txt_i="18250" txt_f="18275">, Supplementary Table 4).</offsets><fig id="fig0015"><label><offsets xml_i="33035" xml_f="33041" txt_i="18275" txt_f="18281">Fig. 3</offsets></label><caption><p><offsets xml_i="33061" xml_f="33302" txt_i="18281" txt_f="18522">Time from 2-yr prostate-specific antigen (PSA) test to (A) PSA failure, (B) biochemical progression-free survival (bPFS) event, (c) metastasis-free survival (MFS) event, (D) prostate cancer (PC)-related death, (E) death; 2-yr PSA population.</offsets></p></caption><graphic xlink:href="gr3"></graphic></fig></p></sec></sec></sec><sec id="sec0140"><label><offsets xml_i="33405" xml_f="33406" txt_i="18527" txt_f="18528">4</offsets></label><title><offsets xml_i="33421" xml_f="33431" txt_i="18528" txt_f="18538">Discussion</offsets></title><p id="par0175"><offsets xml_i="33455" xml_f="33581" txt_i="18539" txt_f="18665">Failure to eradicate local tumours correlates with distant metastases development, cancer-related death, and overall survival </offsets><xref rid="bib0220" ref-type="bibr"><offsets xml_i="33617" xml_f="33621" txt_i="18665" txt_f="18669">[15]</offsets></xref><offsets xml_i="33628" xml_f="33630" txt_i="18669" txt_f="18671">, </offsets><xref rid="bib0225" ref-type="bibr"><offsets xml_i="33666" xml_f="33670" txt_i="18671" txt_f="18675">[16]</offsets></xref><offsets xml_i="33677" xml_f="33773" txt_i="18675" txt_f="18771"> and presently, post-RT prostate biopsy remains the only direct measure of local tumour control </offsets><xref rid="bib0230" ref-type="bibr"><offsets xml_i="33809" xml_f="33813" txt_i="18771" txt_f="18775">[17]</offsets></xref><offsets xml_i="33820" xml_f="33854" txt_i="18775" txt_f="18809">. In agreement with other studies </offsets><xref rid="bib0165" ref-type="bibr"><offsets xml_i="33890" xml_f="33893" txt_i="18809" txt_f="18812">[4]</offsets></xref><offsets xml_i="33900" xml_f="33902" txt_i="18812" txt_f="18814">, </offsets><xref rid="bib0220" ref-type="bibr"><offsets xml_i="33938" xml_f="33942" txt_i="18814" txt_f="18818">[15]</offsets></xref><offsets xml_i="33949" xml_f="33951" txt_i="18818" txt_f="18820">, </offsets><xref rid="bib0225" ref-type="bibr"><offsets xml_i="33987" xml_f="33991" txt_i="18820" txt_f="18824">[16]</offsets></xref><offsets xml_i="33998" xml_f="34000" txt_i="18824" txt_f="18826">, </offsets><xref rid="bib0235" ref-type="bibr"><offsets xml_i="34036" xml_f="34040" txt_i="18826" txt_f="18830">[18]</offsets></xref><offsets xml_i="34047" xml_f="34049" txt_i="18830" txt_f="18832">, </offsets><xref rid="bib0240" ref-type="bibr"><offsets xml_i="34085" xml_f="34089" txt_i="18832" txt_f="18836">[19]</offsets></xref><offsets xml_i="34096" xml_f="34409" txt_i="18836" txt_f="19149">, our results show that prostate biopsies performed between 18 mo and 36 mo after RT are highly prognostic of future biochemical failure and disease–free status at 10 yr. As reported in previous studies, we found similar prognostic value for indeterminate and negative biopsies for subsequent biochemical failure </offsets><xref rid="bib0220" ref-type="bibr"><offsets xml_i="34445" xml_f="34449" txt_i="19149" txt_f="19153">[15]</offsets></xref><offsets xml_i="34456" xml_f="34458" txt_i="19153" txt_f="19155">, </offsets><xref rid="bib0230" ref-type="bibr"><offsets xml_i="34494" xml_f="34498" txt_i="19155" txt_f="19159">[17]</offsets></xref><offsets xml_i="34505" xml_f="34507" txt_i="19159" txt_f="19161">, </offsets><xref rid="bib0235" ref-type="bibr"><offsets xml_i="34543" xml_f="34547" txt_i="19161" txt_f="19165">[18]</offsets></xref><offsets xml_i="34554" xml_f="34556" txt_i="19165" txt_f="19167">, </offsets><xref rid="bib0245" ref-type="bibr"><offsets xml_i="34592" xml_f="34596" txt_i="19167" txt_f="19171">[20]</offsets></xref><offsets xml_i="34603" xml_f="34604" txt_i="19171" txt_f="19172">.</offsets></p><p id="par0180"><offsets xml_i="34624" xml_f="34679" txt_i="19173" txt_f="19228">We recognise the low positive biopsy rate in our study </offsets><xref rid="bib0220" ref-type="bibr"><offsets xml_i="34715" xml_f="34719" txt_i="19228" txt_f="19232">[15]</offsets></xref><offsets xml_i="34726" xml_f="34728" txt_i="19232" txt_f="19234">, </offsets><xref rid="bib0230" ref-type="bibr"><offsets xml_i="34764" xml_f="34768" txt_i="19234" txt_f="19238">[17]</offsets></xref><offsets xml_i="34775" xml_f="34898" txt_i="19238" txt_f="19361">. In particular, the differences between our study and RTOG 9408 which reported a 30% positive biopsy rate are of interest </offsets><xref rid="bib0240" ref-type="bibr"><offsets xml_i="34934" xml_f="34938" txt_i="19361" txt_f="19365">[19]</offsets></xref><offsets xml_i="34945" xml_f="35567" txt_i="19365" txt_f="19987">. Potential causes for our lower biopsy positive rate include the use of dose escalation in 50% of the patients who had a considerably lower rate of positive biopsies (74 Gy 4% vs 64 Gy 12%), the use of 6 mo rather than 4 mo androgen suppression and the strict exclusion of patients who had PSA failure at the 2-yr time point. In our EG who had PSA failure before or on the date of their 2-yr biopsy, 41% had positive biopsies. Finally, our study used two to four biopsies and a higher positive biopsy rate might have been found if more comprehensive prostate sampling had been employed particularly if using MRI guidance.</offsets></p><p id="par0185"><offsets xml_i="35587" xml_f="35684" txt_i="19988" txt_f="20085">We previously reported that 39% (91/236) of deaths in the RT01 trial were due to prostate cancer </offsets><xref rid="bib0195" ref-type="bibr"><offsets xml_i="35720" xml_f="35724" txt_i="20085" txt_f="20089">[10]</offsets></xref><offsets xml_i="35731" xml_f="36238" txt_i="20089" txt_f="20596"> and PCSS is a more appropriate outcome measure for assessing the value of positive prostate biopsies than overall survival. We observed significantly poorer PCSS in patients with positive 2-yr biopsies with HR of 15.6 and 9.8 in the PPG and LPG groups, respectively; however, our evidence is limited due to the small number of deaths (4/27 in PPG group), which probably relates to case selection for biopsy excluding patients with early PSA failure. Nevertheless, the data is in accord with Zelefsky et al </offsets><xref rid="bib0220" ref-type="bibr"><offsets xml_i="36274" xml_f="36278" txt_i="20596" txt_f="20600">[15]</offsets></xref><offsets xml_i="36285" xml_f="36485" txt_i="20600" txt_f="20800"> who demonstrated a three-fold increase in the rate of deaths from prostate cancer after 10-yr follow-up after a positive biopsy in intermediate- or high-risk prostate cancer patients treated with RT.</offsets></p><p id="par0190"><offsets xml_i="36505" xml_f="37088" txt_i="20801" txt_f="21384">We noted that early biochemical failure correlates with a higher positive biopsy rate when compared with the general PPG; this could be attributed to early local recurrence reflecting more aggressive tumours. We also observed that biochemical failure does not always correlate with positive biopsies as 27/46 (59%) of cases with biochemical failure in the EG had negative biopsies. This is probably due to the development of extra-prostatic recurrence as the cause of PSA failure or, alternatively missing the recurrent focus of tumour during biopsy, yielding false-negative results.</offsets></p><p id="par0195"><offsets xml_i="37108" xml_f="37438" txt_i="21385" txt_f="21712">PSA values at 2 yr were significantly correlated with biopsy outcomes, bPFS, PCSS, with PSA &gt;1 ng/ml associated with a 2.7 higher chance of future biochemical failure than PSA ≤1 ng/ml. This is in agreement with previous studies reporting the importance of PSA nadir in predicting biochemical failure and disease-free survival </offsets><xref rid="bib0250" ref-type="bibr"><offsets xml_i="37474" xml_f="37478" txt_i="21712" txt_f="21716">[21]</offsets></xref><offsets xml_i="37485" xml_f="37487" txt_i="21716" txt_f="21718">, </offsets><xref rid="bib0255" ref-type="bibr"><offsets xml_i="37523" xml_f="37527" txt_i="21718" txt_f="21722">[22]</offsets></xref><offsets xml_i="37534" xml_f="37536" txt_i="21722" txt_f="21724">, </offsets><xref rid="bib0260" ref-type="bibr"><offsets xml_i="37572" xml_f="37576" txt_i="21724" txt_f="21728">[23]</offsets></xref><offsets xml_i="37583" xml_f="37585" txt_i="21728" txt_f="21730">, </offsets><xref rid="bib0265" ref-type="bibr"><offsets xml_i="37621" xml_f="37625" txt_i="21730" txt_f="21734">[24]</offsets></xref><offsets xml_i="37632" xml_f="37633" txt_i="21734" txt_f="21735">.</offsets></p><p id="par0200"><offsets xml_i="37653" xml_f="37917" txt_i="21736" txt_f="22000">Prostate biopsy has disadvantages; it is an invasive procedure with risk of infection and bleeding. The uptake of biopsies in this study was modest with only 37% compliance. However, this is quite similar to the RTOG 9408 study where 42% of patients were biopsied </offsets><xref rid="bib0240" ref-type="bibr"><offsets xml_i="37953" xml_f="37957" txt_i="22000" txt_f="22004">[19]</offsets></xref><offsets xml_i="37964" xml_f="38223" txt_i="22004" txt_f="22263"> suggesting that this is the realistic proportion of patients who are likely to be suitable and consent to biopsy in such large multi-centre randomised trials. The timing of post-treatment biopsies is problematic and false-positive results occur. Crook et al </offsets><xref rid="bib0165" ref-type="bibr"><offsets xml_i="38259" xml_f="38262" txt_i="22263" txt_f="22266">[4]</offsets></xref><offsets xml_i="38269" xml_f="38638" txt_i="22266" txt_f="22635"> demonstrated that 30% of initially indeterminate biopsies at 13 mo cleared at a mean time of 31.6 mo; this is thought to be secondary to the prolonged killing effect of RT. In this series, two patients had positive biopsies at 2 yr with no evidence of biochemical recurrence 10 yr following RT. Conversely, sampling errors may lead to potential false-negative results.</offsets></p><p id="par0205"><offsets xml_i="38658" xml_f="38758" txt_i="22636" txt_f="22736">Pathology interpretation is not straightforward and different assessment methods have been proposed </offsets><xref rid="bib0225" ref-type="bibr"><offsets xml_i="38794" xml_f="38798" txt_i="22736" txt_f="22740">[16]</offsets></xref><offsets xml_i="38805" xml_f="38807" txt_i="22740" txt_f="22742">, </offsets><xref rid="bib0250" ref-type="bibr"><offsets xml_i="38843" xml_f="38847" txt_i="22742" txt_f="22746">[21]</offsets></xref><offsets xml_i="38854" xml_f="38979" txt_i="22746" txt_f="22871">. In this series, 27% (11/40) of biopsies scored positive by local pathologists were downgraded to indeterminate or negative.</offsets></p><p id="par0210"><offsets xml_i="38999" xml_f="39197" txt_i="22872" txt_f="23070">Since this study multiparametric MRI (mpMRI) of the prostate has become an increasingly reliable method to diagnose loco-regional and distant recurrence combining T2 with diffusion weighted imaging </offsets><xref rid="bib0270" ref-type="bibr"><offsets xml_i="39233" xml_f="39237" txt_i="23070" txt_f="23074">[25]</offsets></xref><offsets xml_i="39244" xml_f="39246" txt_i="23074" txt_f="23076">, </offsets><xref rid="bib0275" ref-type="bibr"><offsets xml_i="39282" xml_f="39286" txt_i="23076" txt_f="23080">[26]</offsets></xref><offsets xml_i="39293" xml_f="39475" txt_i="23080" txt_f="23262">. One recent study comparing mpMRI with histopathology after salvage prostatectomy post-RT showed 50–71% sensitivity with 80–100% specificity for detecting extra-prostatic extension </offsets><xref rid="bib0280" ref-type="bibr"><offsets xml_i="39511" xml_f="39515" txt_i="23262" txt_f="23266">[27]</offsets></xref><offsets xml_i="39522" xml_f="39671" txt_i="23266" txt_f="23415">. A further study reported an area under the curve of 0.84 when using mpMRI to detect local recurrence compared with template transperineal biopsies </offsets><xref rid="bib0285" ref-type="bibr"><offsets xml_i="39707" xml_f="39711" txt_i="23415" txt_f="23419">[28]</offsets></xref><offsets xml_i="39718" xml_f="39825" txt_i="23419" txt_f="23526">. Early results assessing prostate-specific membrane antigen-positron emission tomography appear promising </offsets><xref rid="bib0290" ref-type="bibr"><offsets xml_i="39861" xml_f="39865" txt_i="23526" txt_f="23530">[29]</offsets></xref><offsets xml_i="39872" xml_f="39873" txt_i="23530" txt_f="23531">.</offsets></p><p id="par0215"><offsets xml_i="39893" xml_f="40926" txt_i="23532" txt_f="24565">Despite the association of positive post-RT prostate biopsies with future bPFS and CSS, we would not recommend routine biopsy in line with current practice in the UK. Biopsy remains essential in selected patients led by unfavourable post-treatment PSA profiles combined with MRI in patients suitable and favouring local salvage treatment. Clarification of the role of imaging and biopsy in patients with post-treatment PSA levels 1.0–2.0 ng/ml would be of value. For both the poor prognostic group of patients with PSA failure before 2 yr and an intermediate group with PSA levels 1–2 ng/ml at 2 yr imaging reassessment might be considered. Prostate biopsy would only be indicated after exclusion of extra-pelvic disease and there should be MRI or other imaging evidence of locally persistent disease. The patient must be suitable for and want local salvage treatment. For the good prognosis group of patients with PSA level of ≤1 ng/ml, the recurrence rate is low with excellent long-term outcomes and we would not recommend biopsy.</offsets></p></sec><sec id="sec0145"><label><offsets xml_i="40961" xml_f="40962" txt_i="24567" txt_f="24568">5</offsets></label><title><offsets xml_i="40977" xml_f="40988" txt_i="24568" txt_f="24579">Conclusions</offsets></title><p id="par0220"><offsets xml_i="41012" xml_f="41440" txt_i="24580" txt_f="25008">Prostate biopsies performed 2 yr after radical RT using contemporary doses with neoadjuvant androgen deprivation therapy are rarely positive in patients with PSA ≤2 ng/ml but are associated with poor outcome. PSA failure within 2 yr of RT identifies a population at high risk of death from prostate cancer. PSA-led prostate biopsies post-treatment should be considered in selected patients suitable for local salvage procedures.</offsets></p><p id="par0225"><offsets xml_i="41460" xml_f="41462" txt_i="25009" txt_f="25011">  </offsets><italic><bold><offsets xml_i="41476" xml_f="41497" txt_i="25011" txt_f="25032">Author contributions:</offsets></bold></italic><offsets xml_i="41513" xml_f="41670" txt_i="25032" txt_f="25189"> David Dearnaley had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.  </offsets></p><p id="par0230"><italic><offsets xml_i="41698" xml_f="41723" txt_i="25190" txt_f="25215">Study concept and design:</offsets></italic><offsets xml_i="41732" xml_f="41788" txt_i="25215" txt_f="25271"> Kass-Iliyya, Fisher, Syndikus, Nicol, Sydes, Dearnaley.</offsets></p><p id="par0235"><italic><offsets xml_i="41816" xml_f="41836" txt_i="25272" txt_f="25292">Acquisition of data:</offsets></italic><offsets xml_i="41845" xml_f="41918" txt_i="25292" txt_f="25365"> Jovic, Murphy, Fisher, Syndikus, Jose, Scrase, Graham, Sydes, Dearnaley.</offsets></p><p id="par0240"><italic><offsets xml_i="41946" xml_f="41982" txt_i="25366" txt_f="25402">Analysis and interpretation of data:</offsets></italic><offsets xml_i="41991" xml_f="42036" txt_i="25402" txt_f="25447"> Kass-Iliyya, Jovic, Nicol, Sydes, Dearnaley.</offsets></p><p id="par0245"><italic><offsets xml_i="42064" xml_f="42091" txt_i="25448" txt_f="25475">Drafting of the manuscript:</offsets></italic><offsets xml_i="42100" xml_f="42148" txt_i="25475" txt_f="25523"> Kass-Iliyya, Jovic, Syndikus, Sydes, Dearnaley.</offsets></p><p id="par0250"><italic><offsets xml_i="42176" xml_f="42247" txt_i="25524" txt_f="25595">Critical revision of the manuscript for important intellectual content:</offsets></italic><offsets xml_i="42256" xml_f="42349" txt_i="25595" txt_f="25688"> Kass-Iliyya, Jovic, Murphy, Fisher, Syndikus, Jose, Scrase, Graham, Nicol, Sydes, Dearnaley.</offsets></p><p id="par0255"><italic><offsets xml_i="42377" xml_f="42398" txt_i="25689" txt_f="25710">Statistical analysis:</offsets></italic><offsets xml_i="42407" xml_f="42429" txt_i="25710" txt_f="25732"> Jovic, Murphy, Sydes.</offsets></p><p id="par0260"><italic><offsets xml_i="42457" xml_f="42475" txt_i="25733" txt_f="25751">Obtaining funding:</offsets></italic><offsets xml_i="42484" xml_f="42502" txt_i="25751" txt_f="25769"> Dearnaley, Sydes.</offsets></p><p id="par0265"><italic><offsets xml_i="42530" xml_f="42577" txt_i="25770" txt_f="25817">Administrative, technical, or material support:</offsets></italic><offsets xml_i="42586" xml_f="42594" txt_i="25817" txt_f="25825"> Murphy.</offsets></p><p id="par0270"><italic><offsets xml_i="42622" xml_f="42634" txt_i="25826" txt_f="25838">Supervision:</offsets></italic><offsets xml_i="42643" xml_f="42661" txt_i="25838" txt_f="25856"> Nicol, Dearnaley.</offsets></p><p id="par0275"><italic><offsets xml_i="42689" xml_f="42695" txt_i="25857" txt_f="25863">Other:</offsets></italic><offsets xml_i="42704" xml_f="42712" txt_i="25863" txt_f="25871"> None.  </offsets></p><p id="par0280"><italic><bold><offsets xml_i="42746" xml_f="42768" txt_i="25872" txt_f="25894">Financial disclosures:</offsets></bold></italic><offsets xml_i="42784" xml_f="43187" txt_i="25894" txt_f="26297"> David Dearnaley certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.  </offsets></p><p id="par0285"><italic><bold><offsets xml_i="43221" xml_f="43261" txt_i="26298" txt_f="26338">Funding/Support and role of the sponsor:</offsets></bold></italic><offsets xml_i="43277" xml_f="43983" txt_i="26338" txt_f="27044"> The trial was sponsored by UK Medical Research Council and conducted by the MRC Clinical Trials Unit. Sydes, Jovic, and Murphy are employees of the sponsor at the Medical Research Council Clinical Trials Unit at UCL. MRC employees were central to the conduct of the trial and the development of this manuscript. Sydes and Jovic had access to raw data. The trial was registered on controlled-trials.com as ISRCTN47772397. Dearnaley, Nicol, Fisher, and Kass-Iliyya acknowledge NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and Institute of Cancer Research and Dearnaley has been supported by CRUK Program Awards C33589/A10588, C46/A10588, C46/A3976, C46/A2131.</offsets></p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0150"><label>1</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>J.M.</given-names></name><name><surname>Bahadur</surname><given-names>Y.A.</given-names></name><name><surname>Robertson</surname><given-names>S.J.</given-names></name><name><surname>Perry</surname><given-names>G.A.</given-names></name><name><surname>Esche</surname><given-names>B.A.</given-names></name></person-group><article-title>Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma</article-title><source>Cancer</source><volume>79</volume><year>1997</year><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">8988730</pub-id></element-citation></ref><ref id="bib0155"><label>2</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J.H.</given-names></name><name><surname>Eastham</surname><given-names>J.</given-names></name><name><surname>Macchia</surname><given-names>R.J.</given-names></name></person-group><article-title>Outcomes following negative prostate biopsy for patients with persistent disease after radiotherapy for prostate cancer</article-title><source>Int Braz J Urol</source><volume>36</volume><year>2010</year><fpage>44</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">20202234</pub-id></element-citation></ref><ref id="bib0160"><label>3</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Cheville</surname><given-names>J.C.</given-names></name><name><surname>Bostwick</surname><given-names>D.G.</given-names></name></person-group><article-title>Diagnosis of prostate cancer in needle biopsies after radiation therapy</article-title><source>Am J Surg Pathol</source><volume>23</volume><year>1999</year><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">10524518</pub-id></element-citation></ref><ref id="bib0165"><label>4</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>J.</given-names></name><name><surname>Malone</surname><given-names>S.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name><name><surname>Bahadur</surname><given-names>Y.</given-names></name><name><surname>Robertson</surname><given-names>S.</given-names></name><name><surname>Abdolell</surname><given-names>M.</given-names></name></person-group><article-title>Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>48</volume><year>2000</year><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">10974448</pub-id></element-citation></ref><ref id="bib0170"><label>5</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Zietman</surname><given-names>A.L.</given-names></name><name><surname>Shipley</surname><given-names>W.U.</given-names></name><name><surname>Coen</surname><given-names>J.J.</given-names></name></person-group><article-title>Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup</article-title><source>J Urol</source><volume>152</volume><year>1994</year><fpage>1806</fpage><lpage>1812</lpage><pub-id pub-id-type="pmid">7523726</pub-id></element-citation></ref><ref id="bib0175"><label>6</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Stamey</surname><given-names>T.A.</given-names></name><name><surname>Ferrari</surname><given-names>M.K.</given-names></name><name><surname>Schmid</surname><given-names>H.P.</given-names></name></person-group><article-title>The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients</article-title><source>J Urol</source><volume>150</volume><year>1993</year><fpage>1856</fpage><lpage>1859</lpage><pub-id pub-id-type="pmid">7693982</pub-id></element-citation></ref><ref id="bib0180"><label>7</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Scardino</surname><given-names>P.T.</given-names></name><name><surname>Frankel</surname><given-names>J.M.</given-names></name><name><surname>Wheeler</surname><given-names>T.M.</given-names></name></person-group><article-title>The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer</article-title><source>J Urol</source><volume>135</volume><year>1986</year><fpage>510</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">3944896</pub-id></element-citation></ref><ref id="bib0185"><label>8</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Kurth</surname><given-names>K.H.</given-names></name><name><surname>Altwein</surname><given-names>J.E.</given-names></name><name><surname>Skoluda</surname><given-names>D.</given-names></name><name><surname>Hohenfellner</surname><given-names>R.</given-names></name></person-group><article-title>Followup of irradiated prostatic carcinoma by aspiration biopsy</article-title><source>J Urol</source><volume>117</volume><year>1977</year><fpage>615</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">870712</pub-id></element-citation></ref><ref id="bib0190"><label>9</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Dearnaley</surname><given-names>D.P.</given-names></name><name><surname>Sydes</surname><given-names>M.R.</given-names></name><name><surname>Graham</surname><given-names>J.D.</given-names></name></person-group><article-title>Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial</article-title><source>Lancet Oncol</source><volume>8</volume><year>2007</year><fpage>475</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">17482880</pub-id></element-citation></ref><ref id="bib0195"><label>10</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Dearnaley</surname><given-names>D.P.</given-names></name><name><surname>Jovic</surname><given-names>G.</given-names></name><name><surname>Syndikus</surname><given-names>I.</given-names></name></person-group><article-title>Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial</article-title><source>Lancet Oncol</source><volume>15</volume><year>2014</year><fpage>464</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">24581940</pub-id></element-citation></ref><ref id="bib0200"><label>11</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Sydes</surname><given-names>M.R.</given-names></name><name><surname>Stephens</surname><given-names>R.J.</given-names></name><name><surname>Moore</surname><given-names>A.R.</given-names></name></person-group><article-title>Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer</article-title><source>Radiother Oncol</source><volume>72</volume><year>2004</year><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">15297138</pub-id></element-citation></ref><ref id="bib0205"><label>12</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>A.</given-names></name><name><surname>Roach</surname><given-names>M.</given-names><suffix>3rd</suffix></name><name><surname>Marquez</surname><given-names>C.</given-names></name></person-group><article-title>Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>30</volume><year>1994</year><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">7523343</pub-id></element-citation></ref><ref id="bib0210"><label>13</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>C.C.</given-names></name><name><surname>Dearnaley</surname><given-names>D.P.</given-names></name></person-group><article-title>The management of PSA failure after radical radiotherapy for localized prostate cancer</article-title><source>Radiother Oncol</source><volume>49</volume><year>1998</year><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">10052875</pub-id></element-citation></ref><ref id="bib0215"><label>14</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>D.G.</given-names></name><name><surname>Dore</surname><given-names>C.J.</given-names></name></person-group><article-title>Baseline comparisons in randomized clinical trials</article-title><source>Stat Med</source><volume>10</volume><year>1991</year><fpage>797</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">2068432</pub-id></element-citation></ref><ref id="bib0220"><label>15</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Zelefsky</surname><given-names>M.J.</given-names></name><name><surname>Reuter</surname><given-names>V.E.</given-names></name><name><surname>Fuks</surname><given-names>Z.</given-names></name><name><surname>Scardino</surname><given-names>P.</given-names></name><name><surname>Shippy</surname><given-names>A.</given-names></name></person-group><article-title>Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer</article-title><source>J Urol</source><volume>179</volume><year>2008</year><fpage>1368</fpage><lpage>1373</lpage><comment>discussion 73</comment><pub-id pub-id-type="pmid">18289585</pub-id></element-citation></ref><ref id="bib0225"><label>16</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>N.N.</given-names></name><name><surname>Stock</surname><given-names>R.G.</given-names></name><name><surname>White</surname><given-names>I.</given-names></name><name><surname>Unger</surname><given-names>P.</given-names></name></person-group><article-title>Patterns of local failure following prostate brachytherapy</article-title><source>J Urol</source><volume>177</volume><year>2007</year><fpage>1759</fpage><lpage>1763</lpage><comment>duscussion 63–4</comment><pub-id pub-id-type="pmid">17437808</pub-id></element-citation></ref><ref id="bib0230"><label>17</label><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>J.M.</given-names></name><name><surname>Malone</surname><given-names>S.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name></person-group><article-title>Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial</article-title><source>Cancer</source><volume>115</volume><year>2009</year><fpage>673</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">19117039</pub-id></element-citation></ref><ref id="bib0235"><label>18</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Vance</surname><given-names>W.</given-names></name><name><surname>Tucker</surname><given-names>S.L.</given-names></name><name><surname>de Crevoisier</surname><given-names>R.</given-names></name><name><surname>Kuban</surname><given-names>D.A.</given-names></name><name><surname>Cheung</surname><given-names>M.R.</given-names></name></person-group><article-title>The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>67</volume><year>2007</year><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">17161554</pub-id></element-citation></ref><ref id="bib0240"><label>19</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>D.J.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Bahary</surname><given-names>J.P.</given-names></name></person-group><article-title>Importance of local control in early-stage prostate cancer: outcomes of patients with positive post-radiation therapy biopsy results treated in RTOG 9408</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>92</volume><year>2015</year><fpage>863</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">26104939</pub-id></element-citation></ref><ref id="bib0245"><label>20</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Kestin</surname><given-names>L.L.</given-names></name><name><surname>Goldstein</surname><given-names>N.S.</given-names></name><name><surname>Vicini</surname><given-names>F.A.</given-names></name></person-group><article-title>Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>54</volume><year>2002</year><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">12182980</pub-id></element-citation></ref><ref id="bib0250"><label>21</label><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Zelefsky</surname><given-names>M.J.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Yamada</surname><given-names>Y.</given-names></name></person-group><article-title>Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>75</volume><year>2009</year><fpage>1350</fpage><lpage>1356</lpage><pub-id pub-id-type="pmid">19515504</pub-id></element-citation></ref><ref id="bib0255"><label>22</label><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>DeWitt</surname><given-names>K.D.</given-names></name><name><surname>Sandler</surname><given-names>H.M.</given-names></name><name><surname>Weinberg</surname><given-names>V.</given-names></name><name><surname>McLaughlin</surname><given-names>P.W.</given-names></name><name><surname>Roach</surname><given-names>M.</given-names><suffix>3rd</suffix></name></person-group><article-title>What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?</article-title><source>Urology</source><volume>62</volume><year>2003</year><fpage>492</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">12946753</pub-id></element-citation></ref><ref id="bib0260"><label>23</label><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>M.E.</given-names></name><name><surname>Thames</surname><given-names>H.D.</given-names></name><name><surname>Levy</surname><given-names>L.B.</given-names></name></person-group><article-title>PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>64</volume><year>2006</year><fpage>1140</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">16198506</pub-id></element-citation></ref><ref id="bib0265"><label>24</label><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Critz</surname><given-names>F.A.</given-names></name><name><surname>Levinson</surname><given-names>A.K.</given-names></name><name><surname>Williams</surname><given-names>W.H.</given-names></name><name><surname>Holladay</surname><given-names>D.A.</given-names></name><name><surname>Holladay</surname><given-names>C.T.</given-names></name></person-group><article-title>The PSA nadir that indicates potential cure after radiotherapy for prostate cancer</article-title><source>Urology</source><volume>49</volume><year>1997</year><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">9123692</pub-id></element-citation></ref><ref id="bib0270"><label>25</label><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>V.A.</given-names></name><name><surname>Riches</surname><given-names>S.F.</given-names></name><name><surname>Giles</surname><given-names>S.</given-names></name><name><surname>Dearnaley</surname><given-names>D.</given-names></name><name><surname>deSouza</surname><given-names>N.M.</given-names></name></person-group><article-title>Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy</article-title><source>AJR Am J Roentgenol</source><volume>198</volume><year>2012</year><fpage>596</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">22357998</pub-id></element-citation></ref><ref id="bib0275"><label>26</label><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Westphalen</surname><given-names>A.C.</given-names></name><name><surname>Coakley</surname><given-names>F.V.</given-names></name><name><surname>Roach</surname><given-names>M.</given-names><suffix>3rd</suffix></name><name><surname>McCulloch</surname><given-names>C.E.</given-names></name><name><surname>Kurhanewicz</surname><given-names>J.</given-names></name></person-group><article-title>Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection</article-title><source>Radiology</source><volume>256</volume><year>2010</year><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">20551184</pub-id></element-citation></ref><ref id="bib0280"><label>27</label><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Zattoni</surname><given-names>F.</given-names></name><name><surname>Kawashima</surname><given-names>A.</given-names></name><name><surname>Morlacco</surname><given-names>A.</given-names></name></person-group><article-title>Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil</article-title><source>Pract Radiat Oncol</source><volume>7</volume><year>2017</year><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">27527896</pub-id></element-citation></ref><ref id="bib0285"><label>28</label><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Abd-Alazeez</surname><given-names>M.</given-names></name><name><surname>Ramachandran</surname><given-names>N.</given-names></name><name><surname>Dikaios</surname><given-names>N.</given-names></name></person-group><article-title>Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images</article-title><source>Prostate Cancer Prostatic Dis</source><volume>18</volume><year>2015</year><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">25644248</pub-id></element-citation></ref><ref id="bib0290"><label>29</label><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.K.</given-names></name><name><surname>Watson</surname><given-names>T.</given-names></name><name><surname>Denham</surname><given-names>J.</given-names></name><name><surname>Shakespeare</surname><given-names>T.P.</given-names></name></person-group><article-title>Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>99</volume><year>2017</year><fpage>701</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">29280465</pub-id></element-citation></ref></ref-list><sec id="sec0160" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="par0295"><supplementary-material content-type="local-data" id="upi0005"><media xlink:href="mmc1.docx"></media></supplementary-material></p></sec><fn-group><fn id="sec0155" fn-type="supplementary-material"><label>Appendix A</label><p id="par0290">Supplementary data associated with this article can be found, in the online version, at <ext-link ext-link-type="doi" xlink:href="10.1016/j.eururo.2017.12.017" id="intr0005">https://doi.org/10.1016/j.eururo.2017.12.017</ext-link>.</p></fn></fn-group></back></article>